25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Committee Opinion No. 711 : Opioid Use and Opioid Use Disorder in Pregnancy

      Obstetrics & Gynecology
      Ovid Technologies (Wolters Kluwer Health)

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Opioid use in pregnancy has escalated dramatically in recent years, paralleling the epidemic observed in the general population. To combat the opioid epidemic, all health care providers need to take an active role. Pregnancy provides an important opportunity to identify and treat women with substance use disorders. Substance use disorders affect women across all racial and ethnic groups and all socioeconomic groups, and affect women in rural, urban, and suburban populations. Therefore, it is essential that screening be universal. Screening for substance use should be a part of comprehensive obstetric care and should be done at the first prenatal visit in partnership with the pregnant woman. Patients who use opioids during pregnancy represent a diverse group, and it is important to recognize and differentiate between opioid use in the context of medical care, opioid misuse, and untreated opioid use disorder. Multidisciplinary long-term follow-up should include medical, developmental, and social support. Infants born to women who used opioids during pregnancy should be monitored for neonatal abstinence syndrome by a pediatric care provider. Early universal screening, brief intervention (such as engaging a patient in a short conversation, providing feedback and advice), and referral for treatment of pregnant women with opioid use and opioid use disorder improve maternal and infant outcomes. In general, a coordinated multidisciplinary approach without criminal sanctions has the best chance of helping infants and families.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: not found
          • Article: not found

          Relationship between Nonmedical Prescription-Opioid Use and Heroin Use

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009.

            Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome primarily caused by maternal opiate use. No national estimates are available for the incidence of maternal opiate use at the time of delivery or NAS. To determine the national incidence of NAS and antepartum maternal opiate use and to characterize trends in national health care expenditures associated with NAS between 2000 and 2009. A retrospective, serial, cross-sectional analysis of a nationally representative sample of newborns with NAS. The Kids' Inpatient Database (KID) was used to identify newborns with NAS by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code. The Nationwide Inpatient Sample (NIS) was used to identify mothers using diagnosis related groups for vaginal and cesarean deliveries. Clinical conditions were identified using ICD-9-CM diagnosis codes. NAS and maternal opiate use were described as an annual frequency per 1000 hospital births. Missing hospital charges (<5% of cases) were estimated using multiple imputation. Trends in health care utilization outcomes over time were evaluated using variance-weighted regression. All hospital charges were adjusted for inflation to 2009 US dollars. Incidence of NAS and maternal opiate use, and related hospital charges. The separate years (2000, 2003, 2006, and 2009) of national discharge data included 2920 to 9674 unweighted discharges with NAS and 987 to 4563 unweighted discharges for mothers diagnosed with antepartum opiate use, within data sets including 784,191 to 1.1 million discharges for children (KID) and 816,554 to 879,910 discharges for all ages of delivering mothers (NIS). Between 2000 and 2009, the incidence of NAS among newborns increased from 1.20 (95% CI, 1.04-1.37) to 3.39 (95% CI, 3.12-3.67) per 1000 hospital births per year (P for trend < .001). Antepartum maternal opiate use also increased from 1.19 (95% CI, 1.01-1.35) to 5.63 (95% CI, 4.40-6.71) per 1000 hospital births per year (P for trend < .001). In 2009, newborns with NAS were more likely than all other hospital births to have low birthweight (19.1%; SE, 0.5%; vs 7.0%; SE, 0.2%), have respiratory complications (30.9%; SE, 0.7%; vs 8.9%; SE, 0.1%), and be covered by Medicaid (78.1%; SE, 0.8%; vs 45.5%; SE, 0.7%; all P < .001). Mean hospital charges for discharges with NAS increased from $39,400 (95% CI, $33,400-$45,400) in 2000 to $53,400 (95% CI, $49,000-$57,700) in 2009 (P for trend < .001). By 2009, 77.6% of charges for NAS were attributed to state Medicaid programs. Between 2000 and 2009, a substantial increase in the incidence of NAS and maternal opiate use in the United States was observed, as well as hospital charges related to NAS.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Increasing Incidence and Geographic Distribution of Neonatal Abstinence Syndrome: United States 2009-2012

              Objective Neonatal abstinence syndrome (NAS), a postnatal opioid withdrawal syndrome, increased 3-fold from 2000 to 2009. Since 2009, opioid pain reliever prescriptions and complications increased markedly throughout the US. Understanding recent changes in NAS and its geographic variability would inform state and local governments in targeting public health responses. Study Design We utilized diagnostic and demographic data for hospital discharges from 2009 to 2012 from the Kids’ Inpatient Database and the Nationwide Inpatient Sample. NAS-associated diagnoses were identified utilizing ICD-9-CM codes. All analyses were conducted with nationally weighted data. Expenditure data were adjusted to 2012 US dollars. Between-year differences were determined utilizing least squares regression. Results From 2009 to 2012, NAS incidence increased nationally from 3.4 (95%CI: 3.2-3.6) to 5.8 (95%CI 5.5-6.1) per 1,000 hospital births, reaching a total of 21,732 infants with the diagnosis. Aggregate hospital charges for NAS increased from $732M to $1.5B (p<0.001), with 81% attributed to state Medicaid programs in 2012. NAS incidence varied by geographic Census division, with the highest incidence rate (per 1000 hospital births) of 16.2 (95%CI 12.4-18.9) in the East South Central Division (KY, TN, MS, AL) and the lowest in West South Central Division 2.6 (95%CI 2.3-2.9; [OK, TX, AR, LA]). Conclusion NAS incidence and hospital charges grew substantially during our study period. This costly public health problem merits a public health approach to alleviate harm to women and children. States, particularly in areas of the country most affected by the syndrome, must continue to pursue primary prevention strategies to limit the effects of opioid pain reliever misuse.
                Bookmark

                Author and article information

                Journal
                Obstetrics & Gynecology
                Obstetrics & Gynecology
                Ovid Technologies (Wolters Kluwer Health)
                0029-7844
                2017
                August 2017
                : 130
                : 2
                : e81-e94
                Article
                10.1097/AOG.0000000000002235
                1d4e6eb1-77de-4ce9-b497-b4efe894b49e
                © 2017
                History

                Comments

                Comment on this article